[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100388969":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":20,"locations":29,"responsibleParty":43,"collaborators":46,"id":50,"slug":10,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":10,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":10,"studyType":62,"phases":10,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Patients with a previous diagnosis of ADPKD",null,"Patients that have been diagnosed with ADPKD and meet the study's inclusion criteria",{"label":13,"type":10,"description":14,"interventionNames":10},"Healthy individuals as controls","Age and gender-matched healthy controls",[16],{"name":17,"affiliation":18,"role":19},"Maria V. Irazabal, M.D., Ph.D","Mayo Translational PKD Center, Mayo Clinic","PRINCIPAL_INVESTIGATOR",[21,25],{"name":22,"role":23,"phone":10,"phoneExt":10,"email":24},"Ahmed Abdelfattah","CONTACT","Abdelfattah.Ahmed@mayo.edu",{"name":26,"role":23,"phone":27,"phoneExt":10,"email":28},"Maria V Irazabal, M.D., Ph.D","507-884-5628","irazabalmira.maria@mayo.edu",[30],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":10},"Mayo Clinic in Rochester","RECRUITING","Rochester","Minnesota","55905","United States",{"type":38,"coordinates":39},"Point",[40,41],-92.4699,44.02163,{"lat":41,"lon":40},{"type":19,"investigatorFullName":44,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Maria V. Irazabal Mira","Principal Investigator",[47],{"name":48,"class":49},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","NIH","100388969",false,"NCT04344769","Characterization of the Nrf2 Response in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD)","Inclusion Criteria (ADPKD Subjects):\n\n* ADPKD (based on Ravine et al. criteria)\n* Class 1 B-E according to our imaging classification\n* Male and female subjects 18 - 30 years of age, inclusive\n* Estimated GFR\\> 60 mL\u002Fmin\u002Fm2 (CKD-EPI equation)\n* Ability to provide written, informed consent.\n\nExclusion Criteria (ADPKD Subjects):\n\n* Class 2 according to our imaging classification\n* Concomitant systemic disease in the kidney (e.g. lupus, hepatitis B or C, amyloidosis)\n* Diabetes mellitus (fasting glucose \\> 126 mg\u002FdL or treatment with insulin or oral hypoglycemics).\n* Predicted urine protein excretion in urinalysis \\>1 g\u002F24 hrs\n* Abnormal urinalysis suggestive of concomitant glomerular disease.\n* Subjects having contraindications to, or interference with MRI assessments. \\[For example: ferromagnetic metal prostheses, aneurysm clips, severe claustrophobia, large abdominal\u002Fback tattoos, etc\\].\n* Female subjects that are pregnant\n\nInclusion Criteria (Healthy Subjects):\n\n* Male and female subjects 18 - 30 years of age, inclusive\n* Estimated GFR\\> 60 mL\u002Fmin\u002Fm2 (CKD-EPI equation)\n* Ability to provide written, informed consent.\n\nExclusion Criteria (Healthy Subjects):\n\n* Previous personal or family history of kidney disease.\n* Concomitant systemic disease in the kidney (e.g. lupus, hepatitis B or C, amyloidosis)\n* Diabetes mellitus (fasting glucose \\> 126 mg\u002FdL or treatment with insulin or oral hypoglycemics).\n* Presence of proteinuria\n* Abnormal urinalysis suggestive glomerular disease.\n* Subjects having contraindications to, or interference with MRI assessments. \\[For example: ferromagnetic metal prostheses, aneurysm clips, severe claustrophobia, large abdominal\u002Fback tattoos, etc\\]\n* Female subjects that are pregnant",true,"ALL","18 Years","30 Years",{"count":60,"type":61},40,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to characterize oxidative stress and the Nrf2 antioxidant response in early stages of Autosomal Dominant Polycystic Kidney Disease (ADPKD), while identifying candidate biomarkers.",[65],"Autosomal Dominant Polycystic Kidney Disease",[67,68,69,70],"Oxidative Stress","Antioxidant Response","Nrf2","ADPKD","2026-01-15",{"date":73,"type":74},"2026-01-16","ACTUAL",{"date":76,"type":74},"2019-10-04",{"date":78,"type":61},"2026-12",{"name":5,"class":6},1]